1. Patient must have histologically proven solid tumor malignancy not amenable to curative surgical or radiation therapy.
2. Must not have had prior treatment with bevacizumab, SU11248 or other therapy directed against VEGF
3. Patients must have received ≤ 2 prior systemic treatment regimens.
4. Age ≥ 18 years
5. ECOG performance status 0 or 1.
6. Patients must have normal bone marrow, liver and kidney function.

1. Must have any solid tumor type (e.g., head and neck, breast, lung, gastrointestinal, genitourinary, melanoma, sarcoma, gynecological, or others) that cannot be treated satisfactorily by conventional treatment
2. Must have an ECOG performance status of 0-2
3. Must have adequate bone marrow, liver and kidney function
4. Can have prior chemotherapy and limited radiation
5. Must be 18 years of age or older
6. Must have life expectancy of at least 4 months

Patients must be experiencing therapeutic benefits while receiving treatment with lapatinib through participation in a Phase I study of lapatinib.Patients may be male or female.

1. Patients must have histologically proven metastatic colorectal cancer.
2. Patients must have recovered from the side effects of cytotoxic chemotherapy, radiation treatment and/or major surgery that could interfere with protocol therapy.
3. Patients must have a life expectancy of at least 3 months.

1. Patients must have pathologically-proven primary or recurrent advanced cervical cancer or other pelvic malignancy not amendable to curative surgical resection alone.
2. Patients must have bi-dimensional measurable or clinically estimable disease.
3. Prior chemotherapy and/or radiation is allowable for non-gynecologic cancers as long as appropriate exclusion criteria have been met.
4. Patients have refused or are not candidates for cisplatin chemotherapy as a consequence of renal insufficiency, prior platinum adverse sensitivity, pre-existent neuropathy or intercurrent co-morbid disease are eligible for the study.
5. Patients must have normal liver, kidney and bone marrow function.

1. Patients must have biopsy proven diagnosis of actinic keratoses, Bowen’s disease, squamous cell carcinoma, basal cell carcinoma or mycosis fungoides (stage IA, IIA, IB or IIB for mycosis fungoides)
2. Fitzpatrick skin type I-IV
3. No anticancer therapy within two weeks prior to Pc -PDT
4. Performance status 0-2
5. Patients must have been off photosensitizing medications for the previous two weeks prior to enrollment
6. Patients must not have a significant history of photosensitivity, including a diagnosis of porphyria, lupus erythematosus, xeroderma pigmentosum, severe polymorphous light eruption and solar urticaria
7. Must not have existing diabetes mellitus
8. Must not have know hypersensitivity to ethanol/propylene glycol

1. Patients must have histologically or cytologically confirmed solid tumor or lymphoma for which standard curative or palliative measures do not exist or are no longer effective.
2. Patients with a liver mass, raised alpha-fetoprotein level and positive serology for hepatitis, consistent with a diagnosis or hepatocellular carcinoma will be eligible without the need for pathological confirmation or the diagnosis.
3. Patients with gliomas or brain metastases who require corticosteroids or anticonvulsants must be on a stable dose of corticosteroids and seizure free for one month prior to enrollment.
4. Patients with active hemolysis are not eligible.
5. Patients must have normal bone marrow and kidney function.

1. Patients must have a histologic diagnosis of amyloidosis with a presence of a monoclonal protein determined by either immunoelectrophoresis or immunofixation of the serum or urine.
2. Patients must not have primary amyloidosis manifested only by carpal tunnel syndrome or purpura. Amyloid deposits in a plasmacytoma or in the vessels of a bone marrow in an otherwise asymptomatic individual do not constitute an amyloid syndrome.
3. Patients must not have multiple myeloma defined by the presence of lytic bone disease or greater than 30% bone marrow plasma cells. Patients must not have secondary familial or localized amyloid.
4. Patients must be between 18 and 70 years of age.
5. Patients must have adequate bone marrow, liver and kidney function.

1. Patients must have histologically confirmed diagnosis of advanced solid tumor refractory to standard therapy or for whom there is no standard therapy.
2.  Patients must be at least 21 years of age.
3. Patients must be able to swallow and retain oral medication.
4. Patients must have adequate bone marrow, hepatic and renal function.
5. Patients must not have had any major surgery, hormonal or steroid therapy (other than replacement), chemotherapy, radiotherapy, immunotherapy or other investigational agent within the last 4 weeks (6 weeks for prior nitrosourea or mitomycin C).

1. Patients must have histologic proof of malignancy.

2. Patients must have adequate bone marrow and liver function.  Patients with abnormal kidney function will be allowed and will be grouped accordingly.

3. Patients must be greater than or equal to 18 years of age.

4. Patients must be willing to provide all biologic specimens as required by the protocol.

5. Patients must not have a known standard therapy for patient’s disease that is potentially curative or definitely capable of extending life expectancy.

6. Patients may not receive concurrent chemotherapy, immunotherapy, radiotherapy or concurrent use of other investigational agents (bisphosphonate therapy will not be considered investigational agents for the purpose of trial eligibility).

1. Patients must have relapsed or refractory (progressive) indolent non-Hodgkin’s lymphoma.

2. Patients with non-Hodgkin’s lymphoma must have measurable disease.

3. Patients with relapsed indolent NHL (including CLL) will be enrolled in first, second, third relapse, or indolent NHL patients with progressive disease.

4. Prior fludarabine therapy is allowed; however patients should not have been previously treated with PS-341.

5. Patients who are candidates for potentially curative transplant therapies should not be entered on this study.

6. Patients must have normal bone marrow, hepatic and renal function.

1. Histologically or cytologically confirmed local advanced (Stage III or IV) squamous cell carcinoma of the head and neck without distant metastatic disease
2. Measurable disease
3. 18 years of age or older
4. ECOG performance status of 0, 1, or 2
5. Normal organ and bone marrow function
6. Period of 5 years has elapsed since treatment of any previous cancer except skin cancer or CIS of cervix
7. No clinically significant heart disease
8. Nor prior chemotherapy or radiation therapy
9. No brain metastases
10. Not HIV positive

1. Patients with any evaluable or measurable advanced solid tumor as well as glioma and non-Hodgkin’s lymphoma for whom no curative surgical, radiation therapy or chemotherapy treatment programs are available and standard therapy offers at best a modest clinical benefit.  Patients with primary and metastatic CNS malignancies are eligible.

2. Patients must be between 18 and 70 years of age.

3. Patients must not have had more than two prior chemotherapy regimens for metastatic disease.  Thalidomide and other non-classical non-myelosuppressive agents are not included amongst the regimens.

4. All prior myelosuppressive therapy must have been completed 4 weeks prior to enrollment.

5. Patients must have a life expectancy of at least 12 weeks.

6. Patients must have adequate bone marrow, renal, hepatic, cardiac and pulmonary function.

7. Patients must have histologically negative bone marrow biopsy.